Filing Summary
Lantern Pharma Inc. filed this Form 8-K regarding a Nasdaq listing-compliance notice received on September 25, 2026. The report was signed on October 1, 2026. The filing does not report operating results or financial statements for a reporting period.
Financial and Operating Information
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating metrics. It contains no financial guidance or business outlook.
Nasdaq Compliance Notice and Key Change
- Nasdaq notified the company that its market value of listed securities (MVLS) had remained below the $35 million minimum for 30 consecutive business days.
- Nasdaq also stated that the company did not meet the requirements under Listing Rules 5550(b)(1) and 5550(b)(3).
- The company has until March 24, 2027, to regain compliance. To cure through the MVLS standard, its market value must close at or above $35 million for at least 10 consecutive business days within that period.
Risks and Items to Verify
If the company does not regain compliance by the deadline, it expects Nasdaq to notify it that its securities are subject to delisting from the Nasdaq Capital Market. The filing reports a compliance deficiency, not a completed delisting.
- Check whether Lantern Pharma’s MVLS reaches the required level for 10 consecutive business days before the deadline.
- Verify whether the company regains compliance under another applicable listing standard or receives further Nasdaq notices.
- Monitor for updates on the compliance deadline and any potential delisting action.